Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 10/20 | 0.50 |
| ▸ | TSHR | P16473 | 3/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | ADH1B | P00325 | 1/20 | 0.44 |
| ▸ | ADH1C | P00326 | 1/20 | 0.44 |
| ▸ | ADH1A | P07327 | 1/20 | 0.44 |
| ▸ | ADH4 | P08319 | 1/20 | 0.44 |
| ▸ | ADH7 | P40394 | 1/20 | 0.44 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.40 |
| ▸ | PPARA | Q07869 | 2/20 | 0.39 |
| ▸ | GBA1 | P04062 | 1/20 | 0.38 |
| ▸ | CASP2 | P42575 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL983390 | 1.00 | EPHX1 (0.50) | EPHX1TSHRALDH1A1THRBADH1B | |
| SCHEMBL668300 | 1.00 | EPHX1 (0.50) | EPHX1TSHRALDH1A1THRBADH1B | |
| SCHEMBL7777014 | 1.00 | EPHX1 (0.50) | EPHX1TSHRALDH1A1THRBADH1B | |
| SCHEMBL668098 | 1.00 | EPHX1 (0.50) | EPHX1TSHRALDH1A1THRBADH1B | |
| SCHEMBL5508330 | 1.00 | EPHX1 (0.50) | EPHX1TSHRALDH1A1THRBADH1B | |
| SCHEMBL5504517 | 1.00 | EPHX1 (0.50) | EPHX1TSHRALDH1A1THRBADH1B | |
| SCHEMBL15171894 | 1.00 | EPHX1 (0.50) | EPHX1TSHRALDH1A1THRBADH1B | |
| SCHEMBL41714 | 1.00 | EPHX1 (0.50) | EPHX1TSHRALDH1A1THRBADH1B | |
| SCHEMBL8421553 | 1.00 | EPHX1 (0.50) | EPHX1TSHRALDH1A1THRBADH1B | |
| SCHEMBL7174533 | 1.00 | EPHX1 (0.50) | EPHX1TSHRALDH1A1THRBADH1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5840977-A | CYCLOHEXANOL UREA DERIVATIVE AS INTERMEDIATE | FUJIREBIO INC. (JP) | 1998-11-24 | — | — | US | claimed |
| EP-0612740-A1 | Methods of producing pantothenic acid derivative and its starting materials for producing the same | FUJIREBIO Inc. (JP) | 1994-08-31 | — | — | EP | claimed |
| US-20240018156-A1 | SPIROCYCLIC COMPOUNDS | C4 THERAPEUTICS, INC. (US) | 2024-01-18 | — | — | US | disclosed |
| US-11834412-B2 | Derivatives of aryl hydrocarbon receptor agonists | AZORA THERAPEUTICS, INC. (US) | 2023-12-05 | — | — | US | disclosed |
| US-20230357180-A1 | DEGRADERS AND DEGRONS FOR TARGETED PROTEIN DEGRADATION | C4 THERAPEUTICS, INC. (US) | 2023-11-09 | — | — | US | disclosed |
| US-20230312567-A1 | CAPSID INHIBITORS FOR THE TREATMENT OF HIV | GILEAD SCIENCES, INC. | 2023-10-05 | — | — | US | disclosed |
| US-20230279023-A1 | N/O-Linked Degrons and Degronimers for Protein Degradation | C4 THERAPEUTICS, INC. (US) | 2023-09-07 | — | — | US | disclosed |
| US-20230227408-A1 | DERIVATIVES OF ARYL HYDROCARBON RECEPTOR AGONISTS | AZORA THERAPEUTICS, INC. | 2023-07-20 | — | — | US | disclosed |
| US-20230158152-A1 | PROTEOLYSIS REGULATOR AND METHOD FOR USING SAME | MEDSHINE DISCOVERY INC. (CN) | 2023-05-25 | — | — | US | disclosed |
| US-11247984-B2 | Uracil containing compounds | CV6 THERAPEUTICS (NI) LIMITED (GB) | 2022-02-15 | — | — | US | disclosed |
| US-20210338824-A1 | C40-, C28-, and C-32-Linked Rapamycin Analogs as mTOR Inhibitors | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2021-11-04 | — | — | US | disclosed |
| US-7279468-B2 | Integrin ligands | ABBOTT GMBH & CO. KG (DE) | 2007-10-09 | — | — | US | disclosed |
| US-20070054933-A1 | 17-Heterocyclic-4-azasteroid derivatives as androgen receptor modulators | MERCK & CO., INC (US) | 2007-03-08 | — | — | US | disclosed |
| EP-0838508-B1 | Aqueous ink composition for use in an ink-jet printer | SEIKO EPSON CORP (JP) | 2001-08-29 | — | — | EP | disclosed |
| EP-0612740-B1 | Methods of producing pantothenic acid derivative and its starting materials for producing the same | FUJIREBIO KK (JP) | 1999-09-22 | — | — | EP | disclosed |
| US-5871572-A | COLORANT, WATER, A WATER-SOLUBLE ORGANIC SOLVENT, AND PECTIC ACID | SEIKO EPSON CORPORATION (JP) | 1999-02-16 | — | — | US | disclosed |
| US-5840977-A | CYCLOHEXANOL UREA DERIVATIVE AS INTERMEDIATE | FUJIREBIO INC. (JP) | 1998-11-24 | — | — | US | disclosed |
| EP-0838508-A2 | Aqueous ink composition for use in an ink-jet printer | SEIKO EPSON CORPORATION (JP) | 1998-04-29 | — | — | EP | disclosed |
| US-5719298-A | REACTING PANTOTHENIC ACID ACETONIDE WITH UREA COMPOUND IN THE PRESENCE OF ACYLATING AGENT | FUJIREBIO INC. (JP) | 1998-02-17 | — | — | US | disclosed |
| EP-0612740-A1 | Methods of producing pantothenic acid derivative and its starting materials for producing the same | FUJIREBIO Inc. (JP) | 1994-08-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230312567-A1 | CAPSID INHIBITORS FOR THE TREATMENT OF HIV | HAVCR2, MAVS, CD4 | EPHX1 4146/4885TSHR 4881/4885ALDH1A1 3650/4885 |
| US-20230227408-A1 | DERIVATIVES OF ARYL HYDROCARBON RECEPTOR AGONISTS | AHR, ARNT, NR4A1 | EPHX1 1923/4885TSHR 21/4885ALDH1A1 750/4885 |
| US-11834412-B2 | Derivatives of aryl hydrocarbon receptor agonists | AHR, ARNT, NR4A1 | EPHX1 1923/4885TSHR 21/4885ALDH1A1 750/4885 |
| US-20230158152-A1 | PROTEOLYSIS REGULATOR AND METHOD FOR USING SAME | PSMA6, PSMC1, PSMA1 | EPHX1 3172/4885TSHR 2782/4885ALDH1A1 4341/4885 |
| US-20210338824-A1 | C40-, C28-, and C-32-Linked Rapamycin Analogs as mTOR Inhibitors | MTOR, RICTOR, RPTOR | EPHX1 4779/4885TSHR 3817/4885ALDH1A1 4803/4885 |
| US-20240018156-A1 | SPIROCYCLIC COMPOUNDS | CRBN, XIAP, RBX1 | EPHX1 3151/4885TSHR 3600/4885ALDH1A1 1971/4885 |
| US-20230357180-A1 | DEGRADERS AND DEGRONS FOR TARGETED PROTEIN DEGRADATION | STUB1, MDM2, USP30 | EPHX1 4176/4885TSHR 1595/4885ALDH1A1 3735/4885 |
| US-11247984-B2 | Uracil containing compounds | UNG, DPYD, DUT | EPHX1 1534/4885TSHR 4749/4885ALDH1A1 970/4885 |
| US-20230279023-A1 | N/O-Linked Degrons and Degronimers for Protein Degradation | CRBN, CBL, STUB1 | EPHX1 4127/4885TSHR 1050/4885ALDH1A1 4548/4885 |
| US-20070054933-A1 | 17-Heterocyclic-4-azasteroid derivatives as androgen receptor modulators | AR, SHBG, NR5A1 | EPHX1 3906/4885TSHR 1259/4885ALDH1A1 1800/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.